RhumbLine Advisers’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-94,700
| Closed | -$1.17M | – | 4176 |
|
|
2024
Q4 | $1.17M | Buy |
94,700
+3,121
| +3% | +$35.7K | ﹤0.01% | 2168 |
|
|
2024
Q3 | $1.04M | Sell |
91,579
-3,103
| -3% | -$31.1K | ﹤0.01% | 2252 |
|
|
2024
Q2 | $676K | Buy |
94,682
+5,408
| +6% | +$41.4K | ﹤0.01% | 2461 |
|
|
2024
Q1 | $598K | Buy |
89,274
+3,027
| +4% | +$20.8K | ﹤0.01% | 2555 |
|
|
2023
Q4 | $561K | Sell |
86,247
-60,889
| -41% | -$392K | ﹤0.01% | 2596 |
|
|
2023
Q3 | $1.39M | Sell |
147,136
-332
| -0.2% | -$4K | ﹤0.01% | 2033 |
|
|
2023
Q2 | $2.06M | Sell |
147,468
-34,962
| -19% | -$596K | ﹤0.01% | 1891 |
|
|
2023
Q1 | $3.42M | Buy |
182,430
+10,302
| +6% | +$169K | ﹤0.01% | 1539 |
|
|
2022
Q4 | $2.37M | Buy |
172,128
+4,513
| +3% | +$69.1K | ﹤0.01% | 1690 |
|
|
2022
Q3 | $3.21M | Buy |
167,615
+5,543
| +3% | +$101K | ﹤0.01% | 1501 |
|
|
2022
Q2 | $2.47M | Buy |
162,072
+44,636
| +38% | +$660K | ﹤0.01% | 1658 |
|
|
2022
Q1 | $2.39M | Sell |
117,436
-25,569
| -18% | -$521K | ﹤0.01% | 1717 |
|
|
2021
Q4 | $4.17M | Buy |
143,005
+77,823
| +119% | +$2.23M | 0.01% | 1462 |
|
|
2021
Q3 | $1.41M | Buy |
65,182
+2,086
| +3% | +$50.4K | ﹤0.01% | 2075 |
|
|
2021
Q2 | $1.62M | Sell |
63,096
-4,224
| -6% | -$90.2K | ﹤0.01% | 2042 |
|
|
2021
Q1 | $1.23M | Sell |
67,320
-2,920
| -4% | -$48.5K | ﹤0.01% | 2119 |
|
|
2020
Q4 | $811K | Buy |
70,240
+4,333
| +7% | +$39.6K | ﹤0.01% | 2234 |
|
|
2020
Q3 | $502K | Sell |
65,907
-9,265
| -12% | -$70.2K | ﹤0.01% | 2288 |
|
|
2020
Q2 | $494K | Buy |
75,172
+3,888
| +5% | +$21.7K | ﹤0.01% | 2349 |
|
|
2020
Q1 | $364K | Buy |
71,284
+283
| +0.4% | +$1.71K | ﹤0.01% | 2311 |
|
|
2019
Q4 | $545K | Buy |
71,001
+313
| +0.4% | +$1.83K | ﹤0.01% | 2325 |
|
|
2019
Q3 | $375K | Buy |
70,688
+92
| +0.1% | +$571 | ﹤0.01% | 2457 |
|
|
2019
Q2 | $395K | Buy |
70,596
+5,795
| +9% | +$23.9K | ﹤0.01% | 2464 |
|
|
2019
Q1 | $275K | Sell |
64,801
-2,050
| -3% | -$8.36K | ﹤0.01% | 2592 |
|
|
2018
Q4 | $274K | Buy |
66,851
+23,095
| +53% | +$121K | ﹤0.01% | 2586 |
|
|
2018
Q3 | $300K | Sell |
43,756
-668
| -2% | -$3.96K | ﹤0.01% | 2514 |
|
|
2018
Q2 | $174K | Buy |
+44,424
| New | +$154K | ﹤0.01% | 2773 |
|
|
2016
Q2 | – | Sell |
-24,663
| Closed | -$73K | – | 3031 |
|
|
2016
Q1 | $73K | Buy |
24,663
+2,233
| +10% | +$12K | ﹤0.01% | 2934 |
|
|
2015
Q4 | $184K | Buy |
22,430
+2,675
| +14% | +$21.6K | ﹤0.01% | 2826 |
|
|
2015
Q3 | $141K | Buy |
19,755
+1,022
| +5% | +$8.53K | ﹤0.01% | 2887 |
|
|
2015
Q2 | $172K | Sell |
18,733
-1,450
| -7% | -$13.9K | ﹤0.01% | 2933 |
|
|
2015
Q1 | $191K | Buy |
20,183
+4,543
| +29% | +$43.7K | ﹤0.01% | 2841 |
|
|
2014
Q4 | $152K | Sell |
15,640
-1,174
| -7% | -$11.8K | ﹤0.01% | 2884 |
|
|
2014
Q3 | $160K | Buy |
16,814
+1,700
| +11% | +$19K | ﹤0.01% | 2835 |
|
|
2014
Q2 | $199K | Buy |
15,114
+2,870
| +23% | +$36.2K | ﹤0.01% | 2842 |
|
|
2014
Q1 | $163K | Sell |
12,244
-905
| -7% | -$11.9K | ﹤0.01% | 2838 |
|
|
2013
Q4 | $128K | Sell |
13,149
-357
| -3% | -$3.36K | ﹤0.01% | 2935 |
|
|
2013
Q3 | $133K | Buy |
13,506
+359
| +3% | +$3.57K | ﹤0.01% | 2895 |
|
|
2013
Q2 | $119K | Buy |
+13,147
| New | +$138K | ﹤0.01% | 3202 |
|
Other funds holding CDMO
RhumbLine Advisers's CDMO Position: Q1 2025 in Review
RhumbLine Advisers sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 94,700 shares — an estimated $1.17M sold.
RhumbLine Advisers first reported a position in CDMO in Q2 2013 and held it in 39 quarters. The position peaked at $4.17M in Q4 2021. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.
- RhumbLine Advisers reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- RhumbLine Advisers sold 94,700 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $1.17M.
- RhumbLine Advisers first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2013 and held it in 39 quarters.
- RhumbLine Advisers's Avid Bioservices, Inc. Common Stock position peaked at $4.17M in Q4 2021.
- 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.
Based on RhumbLine Advisers's 13F filing for Q1 2025, filed 8 Apr 2025.